IMU

4.00%

4.8¢ imugene limited

Ann: Imugene Images and Follows CHECKVacc in TNBC Patients, page-33

First 33 Last

Share
Profile

Follow
reon1

1,535 Posts.

510

20/04/23

09:45

Post #: 67369519
Share

Originally posted by davybabyk: ↑

Well - I have had a closer look at the poster. Two really interesting things leap out at me.

First up - it tells us the actual dose level escalation plan. At last!

Cohort 1 was just 10 to the 5th - which we knew. 100,000 PFU - A "teeny weeny dose" a Prof Fong put it.

Cohort 2 was 3 times that - 300,000. Still a trivial dose.

AT Cohort 3 they escalated to 10 to the 6th - 1 million PFU - still very low really, but tarting to reach the point where (based on mice result) we might see the start of actual effectiveness. Cohort 4 will be 3 x that or 3 million - then they escalate by an order of magnitude again, to 10 to the 7th (10 million PFY, then, 3 x that for the next cohort etc.

So - the data in the presentation at the conference is only for patients who have been in Cohorts 1, 2 or 3. Ie - most of the 8 patients were at dose levels too small to expect anything remarkable in terms of impact. I assume the first 3 were at Cohort 1. The second group of 3 at Cohort 2, so maybe just 2 patients at Cohort 3.

Cohort 3 - 1 million PFU, is getting into the lower end of what might be a clinically effective dose (based on what the saw in mice, and taking into account that humans are around 3,500 larger than mice).

So - for me the standout fascinating item I the picture in Figure B showing a cancer lesion that has necrosis - ie it is falling apart - with the statement: B) Patient COH-008 received CF33-hNIS-antiPD-L1 at DL3 (1x106 PFU). Injected lesions were superior left chest wall nodules. Injected nodules demonstrated necrosis on clinical exam

This is huge news. We are seeing CF33 killing cancer.

Cheers

Dave

Expand

Good spotting Davy, I have been wondering about that

IMU Price at posting: 14.0¢ Sentiment: Buy Disclosure: Held
16 Upvote

0 Great analysis

Reply

Top Stories

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

There are more pages in this discussion • 85 more messages in this thread...

First 33 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 4.8¢		Change -0.002(4.00%)		Mkt cap ! $356.9M

Open	High	Low	Value	Volume
5.0¢	5.0¢	4.7¢	$2.298M	47.86M

Buyers (Bids)

No.	Vol.	Price($)
5	1925982	4.8¢

Sellers (Offers)

Price($)	Vol.	No.
4.9¢	3452098	12

View Market Depth

No.	Vol.	Price($)
5	1925982	0.048
33	4297134	0.047
47	3841303	0.046
53	6064000	0.045
11	2329545	0.044

Price($)	Vol.	No.
0.049	2620667	8
0.050	2639213	14
0.051	6431004	11
0.052	2071350	7
0.053	418882	5

Last trade - 16.10pm 27/09/2024 (20 minute delay)

IMU (ASX) Chart

Ann: Imugene Images and Follows CHECKVacc in TNBC Patients, page-33

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

ACCC seeks Olam divestments before it can buy Namoi Cotton

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Imugene Images and Follows CHECKVacc in TNBC Patients, page-33

Top Stories

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

ACCC seeks Olam divestments before it can buy Namoi Cotton

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News